Skip to main content
ABVX
NASDAQ Life Sciences

Abivax Upsizes Public Offering to $800M at Premium, Extends Cash Runway into Q2 2029

Analysis by Wiseek AI
Sentiment info
Positive
Importance info
9
Price
$138.379
Mkt Cap
$7.591B
52W Low
$7.41
52W High
$148.83
52W Position info
1767% above low
Off High info
7.0% below high
Rel. Volume info
4.7× avg
Market data snapshot near publication time

ABVX has more than doubled off its 52-week low of $7.41 on elevated volume (4.7× avg).

Summary

Abivax has successfully priced an upsized $800 million public offering of ADSs at a premium, securing substantial capital to fund the commercialization of its lead drug and extend its financial runway.


Key Events · Financing and Capital Events · ABVX

  • Offering Priced and Upsized

    Abivax priced its public offering of 6,400,000 American Depositary Shares (ADSs) at $125.00 per ADS, increasing the offering size from $600 million to $800 million.

  • Premium Pricing Achieved

    The offering was priced at a 2.39% premium to the three-day volume-weighted average price (VWAP) of its ordinary shares on Euronext, indicating strong investor demand.

  • Extended Cash Runway

    The $800 million in gross proceeds is expected to extend the company's cash runway into Q2 2029, supporting potential commercialization of obefazimod and continued clinical development.

  • Potential for Additional Capital

    Underwriters have an option to purchase an additional 960,000 ADSs, which could bring total gross proceeds to $920 million if fully exercised.


Analysis · ABVX · Life Sciences

This filing finalizes the terms of a significant capital raise, upsized from $600 million to $800 million, and priced at a 2.39% premium to the three-day volume-weighted average price. The successful offering, which will result in approximately 8.0% dilution, provides critical funding for the potential commercialization of its lead drug candidate, obefazimod, and further clinical development, extending the company's cash runway into Q2 2029. This demonstrates strong investor confidence following recent positive Phase 3 clinical trial results for obefazimod.

At the time of this filing, ABVX was trading at $138.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $7.41 to $148.83. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABVX - Latest Insights

ABVX
Jul 01, 2026, 9:16 AM EDT
Filing Type: FWP
Importance Score:
9
Price at Filing: $138.38
Real-time Price: $136.58 info
Change: -$1.80 (-1%) info
Market Cap: $10.524B info
ABVX
Jul 01, 2026, 8:37 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $137.20
Real-time Price: $136.58 info
Change: -$0.620 (-0.45%) info
Market Cap: $10.524B info
ABVX
Jun 30, 2026, 5:29 PM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $133.98
Real-time Price: $136.58 info
Change: +$2.60 (+2%) info
Market Cap: $10.524B info
ABVX
Jun 30, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $134.30
Real-time Price: $136.58 info
Change: +$2.28 (+2%) info
Market Cap: $10.524B info
ABVX
Jun 30, 2026, 4:45 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $132.48
Real-time Price: $136.58 info
Change: +$4.10 (+3%) info
Market Cap: $10.524B info
ABVX
Jun 29, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $96.15
Real-time Price: $136.58 info
Change: +$40.43 (+42%) info
Market Cap: $10.524B info
ABVX
Jun 02, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $90.32
Real-time Price: $136.58 info
Change: +$46.26 (+51%) info
Market Cap: $10.524B info
ABVX
Jun 01, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $129.69
Real-time Price: $136.58 info
Change: +$6.89 (+5%) info
Market Cap: $10.524B info
ABVX
May 22, 2026, 4:12 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $122.03
Real-time Price: $136.58 info
Change: +$14.55 (+12%) info
Market Cap: $10.524B info
ABVX
May 20, 2026, 4:47 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $120.48
Real-time Price: $136.58 info
Change: +$16.10 (+13%) info
Market Cap: $10.524B info